WELL Health: Canaccord Increases Price Target To $8.50 Following Bought Deal

This morning Canaccord Genuity raised their 12-month price target on WELL Health Technologies (TSX: WELL) to C$8.50 from C$8.00 and reiterated their Speculative Buy recommendation on the stock following the close of their recent $80 million bought deal.

Doug Taylor, Canaccord’s analyst, now estimates that the company holds roughly $114 million in pro forma cash. Funds from the recent financing are expected to go towards “organic growth initiatives, including its recent apps.health launch, and for additional M&A and strategic investments.”

Taylor says, “Financing strengthens an already sizable war chest for accretive capital allocation.” He adds that the sizeable $114 million in cash WELL has now will go towards M&A or a list of strategic investments, such as the following.

  1. Medical and/or allied health clinics (WELL Health Clinic Network and WELL Allied)
  2. EMR platforms (WELL EMR)
  3. Digital health companies with an emphasis on patient engagement technologies (WELL Digital Health Apps)
  4. Cybersecurity (Cycura)

Although since the Circle Medical deal that was signed at the beginning of September, there has been no new deals, Taylor says, “we understand
the company currently has on the order of 10 signed letters of intent (LOI) in its M&A pipeline, noting that timing and probability of closing from the LOI stage are variable.”

Taylor then touches on their forecast for WELL’s third-quarter results, which will be announced in November. Taylor says that they expect a small growth in Digital Services revenue over the second quarter. This quarter will include early contributions from the Cycura acquisition.

Taylor expects third-quarter revenue to be $11 million and Adjusted EBITDA to be ($0.4) million. His full 2020 year revenue estimate is $44 million with EBITDA of ($0.8) million.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Silver47 Kicks Off 7,000-Meter Drill Campaign at Nevada’s Hughes Project

CBS News Cuts Staff and Shuts Radio Network in Early Bari Weiss Era

Related News

BMO: Tronox Holdings $27 Buyout Offer Is Underwhelming

On September 13, Reuters News reported that Apollo Global Management approached Tronox Holdings (NYSE: TROX)...

Wednesday, September 15, 2021, 03:13:00 PM

Stifel-GMP: Canopy Growth CEO’s Legacy is “Poor Execution, Misallocated Capital, and Mismanaged Expectations.”

Earlier this month, Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) reported their fiscal second-quarter 2022...

Sunday, November 21, 2021, 12:03:00 PM

Canaccord: IAMGOLD Has “Few Desirable Options To Plug Funding Gap”

On May 3, IAMGOLD Corporation (TSX: IMG) reported its first quarter results for 2022. The...

Thursday, May 5, 2022, 02:24:00 PM

Meta Platforms: BMO Reiterates Market Perform Rating, Lowers Target To $222

Last week Meta Platforms (NASDAQ: FB) reported its first-quarter financial results. The company saw its...

Sunday, May 1, 2022, 01:08:00 PM

Canaccord Reiterates $10 Price Target On Blackberry Following Results

On September 22, BlackBerry Limited (TSX: BB) reported their second quarter financial results for the...

Friday, September 24, 2021, 10:52:00 AM